From humans to canines: Unraveling the impact of metabolic health on mammary cancer across species

De humanos a caninos: Desentrañando el impacto de la salud metabólica en el cáncer de mama entre especies

De humanos a caninos: Desvendando o impacto da saúde metabólica no câncer de mama entre espécies

William F. Osorio-Zambrano[1] ; Fabián D. López-Valbuena[2] ; Luis M. Montoya-Flórez[2]*

[1]Universidad Nacional de Colombia, Facultad de Medicina Veterinaria y de Zootecnia, Microbiology and Epidemiology Research Group, Bogotá, Colombia.
[2]Universidad Nacional de Colombia, Facultad de Medicina Veterinaria y de Zootecnia, Veterinary Pathology Research Group

Abstract

Background: The relationship between metabolic health and breast cancer has emerged as an expanding area of research in comparative oncology, particularly highlighted in studies conducted among humans and canines. **Objective:** This review explores how dietary habits, obesity, and metabolic syndromes influence the risk, progression, and response to breast cancer treatments. **Methods:** To this end, the impact of obesity, diet, and lifestyle on carcinogenesis mechanisms and prognosis in human and canine patients affected by mammary tumors was examined. **Results:** By examining comparative studies addressing the relationship between metabolic health and breast cancer in women and canines, common molecular and biochemical pathways in both species were identified. **Conclusions:** This approach provides a broader understanding of oncological diseases and their development, suggesting potential strategies for the prevention, diagnosis, and treatment of breast cancer from a metabolic perspective. However, as this area of research is still developing, it is necessary to explore new research lines to fully understand the complex relationship between metabolic health and cancer across different species from biochemical, molecular, genetic, and epigenetic perspectives. The goal is to gain valuable knowledge that contributes to the development of new diagnostic, prognostic, and therapeutic tools.

Keywords: *biomarkers; breast cancer; canine mammary tumor; comparative oncology; diet and lifestyle; insulin resistance; metabolic health; obesity.*

Resumen

Antecedentes: La relación entre la salud metabólica y el cáncer de mama ha emergido como un área en expansión en la oncología comparativa, destacada especialmente en estudios realizados entre

humanos y caninos. **Objetivo:** Esta revisión explora cómo los hábitos dietéticos, la obesidad y los síndromes metabólicos influyen en el riesgo, la progresión y la respuesta a los tratamientos contra el cáncer de mama. **Métodos:** Con este fin, se examina el impacto de la obesidad, la dieta y el estilo de vida en los mecanismos de carcinogénesis y el pronóstico en pacientes humanos y caninos afectados por tumores mamarios. **Resultados:** Al revisar estudios comparativos que abordan la relación entre la salud metabólica y el cáncer de mama en mujeres y caninos, se identifican vías moleculares y bioquímicas comunes en ambas especies. **Conclusiones:** Este enfoque proporciona una comprensión más amplia de las enfermedades oncológicas y su desarrollo, sugiriendo estrategias potenciales para la prevención, el diagnóstico y el tratamiento del cáncer de mama desde una perspectiva metabólica. Sin embargo, dado que esta área de investigación está en desarrollo, es necesario explorar nuevas líneas de investigación para comprender completamente la compleja relación entre la salud metabólica y el cáncer en diferentes especies desde perspectivas bioquímicas, moleculares, genéticas y epigenéticas. El objetivo es obtener conocimientos valiosos que contribuyan al desarrollo de nuevas herramientas diagnósticas, pronósticas y terapéuticas.

Palabras clave: *biomarcadores; cáncer de mama; dieta y estilo de vida; obesidad; oncología comparativa; resistencia a la insulina; salud metabólica; tumor mamario canino.*

Resumo

Antecedentes: A relação entre saúde metabólica e câncer de mama emergiu como uma área em expansão na oncologia comparativa, especialmente destacada em estudos conduzidos entre humanos e caninos. **Objetivo:** Esta revisão explora como hábitos alimentares, obesidade e síndromes metabólicas influenciam o risco, a progressão e a resposta aos tratamentos contra o câncer de mama. **Métodos:** Para isso, examina-se o impacto da obesidade, da dieta e do estilo de vida nos mecanismos de carcinogênese e no prognóstico em pacientes humanos e caninos afetados por tumores mamários. **Resultados:** Ao examinar estudos comparativos que abordam a relação entre saúde metabólica e câncer de mama em mulheres e caninos, foram identificadas vias moleculares e bioquímicas comuns em ambas as espécies. **Conclusões:** Este enfoque proporciona uma compreensão mais ampla das doenças oncológicas e seu desenvolvimento, sugerindo estratégias potenciais para a prevenção, diagnóstico e tratamento do câncer de mama sob uma perspectiva metabólica. No entanto, dado que esta área de pesquisa ainda está em desenvolvimento, é necessário explorar novas linhas de pesquisa para compreender completamente a complexa relação entre saúde metabólica e câncer em diferentes espécies a partir de perspectivas bioquímicas, moleculares, genéticas e epigenéticas. O objetivo é obter conhecimentos valiosos que contribuam para o desenvolvimento de novas ferramentas de diagnóstico, prognóstico e terapêuticas.

Palavras-chave: *biomarcadores; câncer de mama; dieta e estilo de vida; obesidade; oncologia comparativa; resistência à insulina; saúde metabólica; tumor mamário canino.*

Introduction

In the dynamic domain of oncology, the intricate relationship between metabolic health and mammary cancer across species, particularly in women and canines, prompts a reassessment of conventional cancer care strategies. This review merges insights from evolving breast cancer research in women with studies in canine mammary cancer, drawing on comparative oncological studies to highlight overlap and translational benefits. With recent literature as a basis, we delve into the complex interplay of diet, obesity, and metabolic syndromes, examining their impact on mammary cancer risk, progression, and therapeutic outcomes. Initially, we discuss the role of metabolic health in breast cancer among women, examining how factors like obesity, diet, and insulin resistance influence disease outcomes. Shifting focus to canine mammary cancer, we explore how similar factors affect tumor development and progression in dogs, enriching our understanding of the disease in veterinary medicine. By offering a comparative analysis between human and canine mammary cancer, this review aims to uncover shared

pathways and therapeutic targets, advancing diagnostic and treatment approaches in both fields. Through this approach, we emphasize the significance of a more holistic and cross-disciplinary approach to cancer research, highlighting the importance of understanding the impact of metabolic health on mammary cancer to develop more effective and personalized therapeutic strategies.

Metabolic Health and Breast Cancer in Women

Metabolic Health and Breast Cancer Risk

Metabolic health profoundly impacts breast cancer in multiple ways, yet current research has unveiled complexities that warrant critical examination. For instance, although the potential therapeutic implications arising from comprehending estrogen receptor activity in metabolic balance are intriguing, their clinical translation remains unclear (Mahboobifard et al., 2022). The link between insulin resistance and aggressive breast cancer underscores the importance of comprehensive management strategies, although the effectiveness of existing approaches requires more examination (Guinan et al., 2013). The significant influence of adipocytes on breast cancer progression highlights the necessity of addressing obesity-related factors. In particular, breast cancer promotes the dedifferentiation of adjacent adipocytes into cancer-associated adipocytes, which secrete cytokines and adipokines, facilitating tumorigenesis and metastasis through mechanisms like ECM remodeling and metabolic reprogramming (Wu et al., 2023). However, the efficacy of interventions targeting adipose tissue remains variable. While weight-reducing lifestyle interventions improve adipose tissue function and lower breast cancer risk, adherence to and long-term sustainability of these interventions are challenging (Bhardwaj & Brown, 2021). Comprehensive metabolic evaluations beyond Body Mass Index (BMI), such as measures of insulin resistance, adipokine profiles, and inflammatory markers, are advocated for assessing breast cancer risk. Nevertheless, the practical implementation of these evaluations and their impact on clinical decision-making are still to be fully elucidated (Feigelson et al., 2021; Naaman et al., 2022).

Indeed, while metabolic health profoundly impacts breast cancer risk and outcomes, the mechanistic underpinnings linking obesity and type 2 diabetes to differential susceptibility through insulin, inflammation, and adipose dysfunction require further elucidation (Sankofi et al., 2023). Managing fasting blood glucose and waist circumference is emphasized for prevention, but the optimal thresholds and the true impact on risk reduction require clarification (Haseen et al., 2015; Park et al., 2021). Additionally, understanding metabolic alterations such as the Warburg effect is crucial, although translating this knowledge into effective therapeutic strategies remains challenging (Pereira et al., 2022). Tailored prevention strategies for postmenopausal women are proposed, though their comparative efficacy against broader population-based approaches requires more investigation (Park et al., 2017). The complex interplay between metabolic syndrome and breast cancer characteristics needs further exploration, particularly regarding its implications for personalized treatment approaches (Motoki et al., 2022). For instance, IGF-1 signaling is involved in 87% of invasive breast cancer patients, supporting cancer progression and therapy resistance, which is associated with decreased survival in HER2-positive cases. Additionally, higher IGF-1/IGFBP-3 ratios are linked to poorer outcomes in overweight patients (Tong et al., 2020). While obesity is recognized as a modifiable risk factor, the specific mechanisms through which dysfunctional adipose tissue, insulin signaling, and chronic inflammation contribute to tumorigenesis need deeper investigation (Andò et al., 2020; Nehme et al., 2022).

Although research suggests a correlation between abnormal metabolic markers and

increased breast cancer risk, the clinical utility of these markers, particularly in guiding risk stratification and treatment decisions, remains unclear (Melvin et al., 2017). Similarly, while elevated serum glucose levels correlate with poorer breast cancer prognosis, the causal relationship and implications for treatment remain unclear (Melvin et al., 2017; Ahmed et al., 2023). The imperative of tight glycemic control in diabetic breast cancer patients underscores the need for further investigation into its impact on outcomes and survival (Ahmed et al., 2023). A complex interplay between metabolic health and breast cancer risk is observed, highlighting the importance of continued research to better understand these relationships and their implications for the diagnosis and treatment of breast cancer.

Obesity in Breast Cancer

A critical examination is necessary to explore the profound impact of obesity on breast cancer. While tumor-associated macrophages (TAMs), notably M2 macrophages abundant in the breast cancer microenvironment, are influenced by obesity, the precise mechanisms and their clinical significance remain unclear. Although it is recognized that obesity upregulates estrogen production via CYP19 gene transcription, further investigation is necessary to determine the extent to which this contributes to adverse breast cancer outcomes and the potential for targeted interventions (Rosendahl et al., 2018). Additionally, despite being metabolically healthy, obese women still face elevated risks of obesity-associated cancer mortality, suggesting underlying complexities beyond traditional metabolic markers. The impact of obesity on breast cancer varies with menopausal status and subtype, highlighting the need for diverse approaches to risk assessment and management (Picon-Ruiz et al., 2017; Brantley et al., 2022).

Metabolites related to BMI offer insights into breast carcinogenesis, yet the specific pathways connecting BMI and breast cancer risk require further elucidation. Dysregulated steroid hormone metabolism and branched-chain amino acid metabolism are implicated, but their precise roles in mediating obesity-related breast cancer risks remain incompletely understood (Moore et al., 2018). Similarly, the interaction between obesity and adipocytes influences breast cancer initiation, progression, and metastasis, but the intricate molecular mechanisms driving these processes demand deeper investigation (Balaban et al., 2017; Chu et al., 2019). Hormonal imbalances, particularly elevated estrogen levels, are implicated, yet the potential for targeted interventions remains an area of ongoing research (Zhong et al., 2023). In summary, the impact of obesity on breast cancer involves a complex interplay of molecular, immune, and metabolic mechanisms that require further investigation. While studies have identified associations between obesity and breast cancer risks and outcomes, further research is needed to fully elucidate the underlying pathways and potential therapeutic targets. Additionally, the implications of obesity-induced inflammation on immune responses and treatment outcomes underscore the need for a comprehensive understanding and targeted interventions in managing obesity-related breast cancer risks (Nguyen et al., 2023).

Biomarkers and Metabolomics in Breast Cancer

In the realm of biomarkers and metabolomics in breast cancer, while potential biomarkers show promise for diagnostic, predictive, and therapeutic applications, a critical evaluation is warranted to assess their clinical utility and validity (Table 1). Iron deposits within TAMs and PI3K inhibitors are highlighted for their potential insights into immunotherapy responses and therapy monitoring, but their clinical validation and translation into practice require further scrutiny (Moestue et al., 2013; Leftin et al., 2019). Serum metabolomics have identified potential predictive biomarkers for trastuzumab response in HER2-positive breast cancer, yet their robustness and reproducibility across diverse patient populations remain to be confirmed (Mao et al., 2022). Associations between insulin resistance, hyperglycemia, and

breast cancer progression underscore the need for a comprehensive understanding and targeted interventions. However, translating these findings into clinical practice poses challenges (Durrani et al., 2021; Ahmed et al., 2023). The relationship between the 21-gene recurrence score (RS) and metabolic factors highlights the potential prognostic value of RS in ER-positive, HER2-negative early-stage breast cancer, but its integration into routine clinical practice requires further investigation (Zhu et al., 2021).

In conclusion, various studies highlight the complex interplay between metabolic factors, biomarkers, and breast cancer risk, emphasizing the need for personalized approaches and deeper investigation.

Table 1. Metabolic Health Biomarkers in Human Breast Cancer.

Biomarker	Impact	Potential application	Reference
Insulin resistance	Linked to breast cancer aggressiveness	Management during prevention, diagnosis, and treatment	De Santi et al., 2023; Guinan et al., 2013
Adiponectin	Low levels associated with higher risk	Target for obesity-related interventions	Andò et al., 2020; Nehme et al., 2022
Leptin	High levels promote cancer progression	Target for obesity-related interventions	Taroeno-Hariadi et al., 2021
Resistin	Facilitates breast cancer progression	Prognostic marker	Patrício et al., 2018
Fasting blood glucose	High levels associated with increased risk	Risk assessment and management	Park et al., 2021; Haseen et al., 2015
Waist circumference	Indicator of central obesity linked to higher risk	Risk assessment and lifestyle interventions	Park et al., 2021; Lynch et al., 2010
Body Mass Index	High BMI linked to increased risk, especially in postmenopausal women	Risk assessment and lifestyle interventions	Moore et al., 2018; Feigelson et al., 2021
Estrogen receptor activity	Estrogen promotes tumor growth	Therapeutic target	Mahboobifard et al., 2022
Fibroblast growth factor receptors	Involved in adipose tissue dysfunction	Therapeutic target	Sankofi et al., 2023
PI3K/AKT/mTOR pathway	Involved in cell growth, metabolism, and survival	Therapy monitoring	Moestue et al., 2013
Iron Deposits within TAM	Metabolic marker of tumor microenvironment.	Biomarkers for predicting immunotherapy responses.	Leftin et al., 2019

Metabolic health and canine mammary cancer

Obesity and canine mammary cancer

The intricate association between obesity and canine mammary tumors (CMTs) provides valuable insights into obesity-related cancer risks, drawing comparisons with human contexts. However, while obesity significantly influences CMT onset and progression, our understanding of the underlying mechanisms remains incomplete and calls for critical evaluation (Lim et al., 2015a, Lim et al., 2015b;

Marchi et al., 2022). Associations between leptin, its receptor (ObR), and tumor characteristics suggest potential roles in signaling pathways; nevertheless, further investigation is necessary to elucidate the exact mechanisms involved (Lim et al., 2015a). Additionally, while obesity correlates with increased risks of various tumors, including transitional cell carcinoma and mammary gland tumors, the specific contributions of hormonal and adipokine pathways require more detailed examination (Queiroga et al., 2005; Marchi et al., 2022). Lim et al. (2015) highlight lower ages at CMT onset and higher-grade tumors in overweight or obese dogs, underscoring the need to explore additional factors beyond body condition score (BCS) in CMT development (Lim et al., 2015a). Elevated counts of TAMs in overweight or obese dogs suggest a potential link between obesity-induced inflammation and CMT progression, although the precise mechanisms remain uncertain (Lim et al., 2022). While serum resistin concentrations correlate with tumor aggressiveness and obesity in female dogs with CMTs, the clinical utility of resistin as a prognostic marker requires further validation (Nicchio et al., 2020). Chronic inflammation triggered by obesity may impact aromatase expression and cancer progression, but more comprehensive studies are needed to establish clear parallels with human breast cancer (Shin et al., 2016). Addressing these knowledge gaps through further research is essential for the development of targeted interventions in veterinary oncology.

Metabolic health markers in canine mammary cancer

A review of biomarkers in CMTs underscores their potential as models for human breast cancer (HBC), offering insights into shared epidemiological and histopathological characteristics (Table 2). Elevated serum IL-6 and IL-8 levels in malignant CMTs suggest IL-6 and IL-8 as diagnostic biomarkers, highlighting their importance in prognosis (Ren et al., 2023). Reduced klotho expression is linked to tumor progression, advocating klotho as a prognostic factor (Chung et al., 2022). The presence of CD204-positive TAMs in CMTs indicates M2-polarized macrophage infiltration as a prognostic biomarker, reflecting tumor aggressiveness (Seung et al., 2018). Metabolic reprogramming in CMTs parallels human breast cancer, with potential biomarkers in carbohydrate and lipid metabolism, and plasma-free amino acids, suggesting opportunities for targeted therapy (Marchi et al., 2022; Tamarindo et al., 2023). The impact of obesity on insulin resistance and mammary tumor risks underscores the role of hormones and adipokines as prognostic markers, urging further exploration in both veterinary and human oncology (Marchi et al., 2022). These findings highlight the importance of CMTs in biomarker research, requiring continued investigation to enhance diagnostic and therapeutic strategies in both canine and human oncology.

Table 2. Metabolic Health Biomarkers in Canine Mammary Cancer.

Biomarker	Impact	Potential application	Reference
Adiponectin	Low levels associated with aggressive tumor behavior	Target for obesity-related interventions	Lim et al., 2015a; Marchi et al., 2022
Leptin	Associated with tumor characteristics, independent of body condition	Target for intervention	Queiroga et al., 2005; Marchi et al., 2022
Body condition score (BCS)	Obesity linked to early tumor development and progression	Risk assessment and management in veterinary practice	Lim et al., 2015a

Macrophage infiltration in tumor microenviroment	Indicates a pro-inflammatory state associated with high-grade tumors	Prognostic indicator and therapeutic target	Seung et al., 2018
Aromatase expression	Higher in overweight/obese dogs, involved in hormone-related tumor growth	Therapeutic target in CMT	Lim et al., 2015a; Shin et al., 2016
Resistin	Hyperresistinemia related to tumor aggressiveness and obesity	Prognostic marker in CMT	Nicchio et al., 2020
Insulin resistance	Contributes to mammary tumor risks	Risk assessment	Marchi et al., 2022
IL-6 and IL-8	Pro-inflammatory cytokine associated with tumor progression	Target for immunomodulatory therapy	Irac et al., 2019; Ren et al., 2023

Metabolic health and comparative studies between human and canine mammary cancer

Persistent challenges in human breast cancer research have encouraged the exploration of alternative translational models, such as CMT, which exhibit promising parallels with human breast cancer. Despite a lower mutational burden, CMTs share prevalence, molecular subtypes, and histological traits with HBC, providing valuable insights through comparative studies (Abdelmegeed and Mohammed, 2018; Kwon et al., 2023). Molecular similarities, including steroid receptor expression and mutations in genes like TP53, underscore the relevance of canine models in comparative oncology, offering potential avenues for understanding common signaling pathways and mutations. Challenges persist in HER2 detection, but epigenetic studies propose diagnostic biomarkers like LINE-1 hypomethylation (Bergholtz et al., 2022; Oh and Cho, 2023). Comparative analyses delineate intrinsic molecular subtype similarities and distinctions, providing insights into personalized treatments and highlighting the modeling potential of CMTs (Bergholtz et al., 2022). Cytokine associations in CMTs mirror those in HBC, suggesting potential prognostic markers and therapeutic targets (Irac et al., 2019). Hormone-related aspects, such as low ERα and PR expression in CMTs, parallel risks in HBC, emphasizing the preclinical research potential of canine models (Nguyen et al., 2018). Comparative microRNA expression studies uncover shared genetic characteristics and regulatory mechanisms, offering promising avenues for therapy development. Recent research highlights the roles of miR-21 and miR-29b in both human and canine mammary tumors. Elevated levels of miR-21 serve as a biomarker to differentiate clinically healthy dogs from those with mammary tumors. Furthermore, in breast cancer, elevated miR-21 levels correlate with a worse prognosis. On the other hand, miR-29b, which regulates cell proliferation and metastasis, shows promise as a non-invasive biomarker for both cancers. Notably, miR-29b is overexpressed in human breast cancer cells as well as in the canine mammary gland tumor SNP cell line (Gherman et al., 2024). Understanding miRNA-mediated regulation holds promise for targeted therapies, showcasing the translational impact of comparative oncology in advancing treatments for HBC (Sahabi et al., 2018).

Furthermore, the utilization of canine mammary cancer as a translational model for human breast cancer has broadened our comprehension of cancer and potential therapeutic approaches. Comparative analyses, exemplified by REM-134 radioresistant (RR) cell lines, have unearthed mechanisms of

radioresistance, unveiling parallel pathways (Gray et al., 2020). Additionally, the establishment of living biobanks housing CMT organoids provides valuable insights into tumor biology and treatment outcomes, serving as a platform for preclinical drug assays (Inglebert et al., 2022). Despite inherent differences, CMT models, especially those with PIK3CA mutations in ER+ tumors, exhibit promise in evaluating antiestrogen compounds and combatting therapy resistance. These comparative investigations shed light on shared biological traits and prognostic markers, thereby advancing therapeutic approaches for breast cancer across species.

This review was conducted with the objective of comparing breast cancer in women and mammary cancer in dogs, specifically examining the interplay of diet, obesity, and metabolic syndromes in cancer risk, progression, and therapeutic outcomes. This interdisciplinary approach aims to elucidate shared pathways and therapeutic targets between the two species. By integrating insights from evolving research in both fields, this work seeks to advance understanding of how factors such as obesity, diet, and insulin resistance influence the development and course of mammary cancer. Through this comparative analysis, the study intends to foster translational benefits, ultimately contributing to more effective and personalized diagnostic and therapeutic strategies for both human and veterinary patients with mammary cancer.

Declarations

Funding

Conflicts of interest

The authors declare no conflicts of interest regarding the publication of this paper.

Author contributions

William F. Osorio-Zambrano was responsible for conducting the literature review and drafting the manuscript. Fabián D. López-Valbuena undertook the literature review and adapted the manuscript to conform to the format of the RCCP journal. Luis M. Montoya-Flórez performed the stylistic correction of the manuscript.

Use of artificial intelligence (AI)

We used artificial intelligence (AI) technology (ChatGPT-4) during the preparation of this work solely for the purposes of ensuring correct English grammar, searching for scientific articles, and organizing the references. After using ChatGPT-4, we meticulously reviewed and edited the content. We take full responsibility for the content of this publication.

References

Abdelmegeed SM, Mohammed S. Canine mammary tumors as a model for human disease. Oncol Lett 2018; 15(6): 8195-8205. https://doi.org/10.3892/ol.2018.8411

Ahmed SBM, Radwan N, Amer S, Saheb Sharif-Askari N, Mahdami A, Samara KA, Halwani R, Jelinek HF. Assessing the link between diabetic metabolic dysregulation and breast cancer progression. Int J Mol Sci. 2023; 24(14): 11816. https://doi.org/10.3390/ijms241411816

Andò S, Naimo GD, Gelsomino L, Catalano S, Mauro L. Novel insights into adiponectin action in breast cancer: Evidence of its mechanistic effects mediated by ERα expression. Obes Rev. 2020; 21(5): e13004. https://doi.org/10.1111/obr.13004

Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, Holst J, Saunders DN, Hoy AJ. Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 2017; 5(1). https://doi.org/10.1186/s40170-016-0163-7

Bhardwaj P, Brown KA. Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence. Front Oncol. 2021; 11: 638918 https://doi.org/10.3389/fonc.2021.638918

Brantley KD, Zeleznik OA, Dickerman BA, Balasubramanian R, Clish CB, Avila-Pacheco J, Rosner B, Tamimi RM, Eliassen AH. A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies. Br J Cancer. 2022; 127: 1076-1085. https://doi.org/10.1038/s41416-022-01873-9

Bergholtz H, Lien T, Lingaas F, Sørlie T. Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. J Mammary Gland Biol Neoplasia 2022; 27: 171-183. https://doi.org/10.1007/s10911-022-09523-9

Chu DT, Phuong TNT, Tien NLB, Tran DK, Nguyen TT, Thanh VV, Quang TL, Minh LB, Pham VH, Ngoc VTN, Kushekhar K, Chu-Dinh T. The effects of adipocytes on the regulation of breast cancer in the tumor microenvironment: An update. Cells 2019; 8(8): 857. https://doi.org/10.3390/cells8080857

Chung H, Lee S, Kim GA, Kim WH. Down-expression of klotho in canine mammary gland tumors and its prognostic significance. PLoS One 2022; 17(6): e0265248. https://doi.org/10.1371/journal.pone.0265248

De Santi M, Annibalini G, Marano G, Biganzoli G, Venturelli E, Pellegrini M, Lucertini F, Brandi G, Biganzoli E, Barbieri E, Villarini A. Association between metabolic syndrome, insulin resistance, and IGF-1 in breast cancer survivors of DIANA-5 study. J Cancer Res Clin Oncol. 2023; 149: 8639-8648. https://doi.org/10.1007/s00432-023-04755-6

Durrani IA, Bhatti A, John P. The prognostic outcome of 'type 2 diabetes mellitus and breast cancer' association pivots on hypoxia-hyperglycemia axis. Cancer Cell Int. 2021; 21: 351. https://doi.org/10.1186/s12935-021-02040-5

Feigelson HS, Bodelon C, Powers JD, Curtis RE, Buist DSM, Veiga LHS, Aiello Bowles EJ, Berrington de Gonzalez A, Gierach GL. Body Mass Index and Risk of Second Cancer Among Women With Breast Cancer. JNCI: J Natl Cancer Inst. 2021; 113(9): 1156–1160. https://doi.org/10.1093/jnci/djab053

Gherman LM, Tomuleasa D, Cismaru A, Nutu A, Berindan-Neagoe I. Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier. Med Pharm Rep. 2024; 97(2): 132–142. https://doi.org/10.15386/mpr-2733

Gray M, Turnbull AK, Meehan J, Martínez-Pérez C, Kay C, Pang LY, Argyle DJ. Comparative analysis of the development of acquired radioresistance in canine and human mammary cancer cell lines. Front Vet Sci. 2020; 7: 439. https://doi.org/10.3389/fvets.2020.00439

Guinan EM, Connolly EM, Kennedy MJ, Hussey J. The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study. Nutr J. 2013; 12(99). https://doi.org/10.1186/1475-2891-12-99

Haseen SD, Khanam A, Sultan N, Idrees F, Akhtar N, Imtiaz F. Elevated fasting blood glucose is associated with increased risk of breast cancer: outcome of case-control study conducted in Karachi, Pakistan. Asian Pac J Cancer Prev. 2015; 16(2): 675-678. https://doi.org/10.7314/APJCP.2015.16.2.675

Irac SE, Oksa A, Jackson K, Herndon A, Allavena R, Palmieri C. Cytokine expression in canine lymphoma, osteosarcoma, mammary gland tumor, and melanoma: Comparative aspects. Vet Sci. 2019; 6(2): 37. https://doi.org/10.3390/vetsci6020037

Inglebert M, Dettwiler M, Hahn K, Letko A, Drogemuller C, Doench J, Brown A, Memari Y, Davies HR, Degasperi A, Nik-Zainal S, Rottenberg S. A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. Sci Rep. 2022; 12: 18051. https://

doi.org/10.1038/s41598-022-21706-2

Kwon JY, Moskwa N, Kang W, Fan TM, Lee C. Canine as a Comparative and Translational Model for Human Mammary Tumor. J Breast Cancer. 2023; 26(1): 1–13. https://doi.org/10.4048/jbc.2023.26.e4

Leftin A, Ben-Chetrit N, Joyce JA, Koutcher JA. Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy. Sci Rep. 2019; 9: 857. https://doi.org/10.1038/s41598-018-37408-7

Lim HY, Im KS, Kim NH, Kim HW, Shin JI, Sur JH. Obesity, expression of adipocytokines, and macrophage infiltration in canine mammary tumors. Vet J. 2015a; 203(3): 326–331. https://doi.org/10.1016/j.tvjl.2015.01.005

Lim HY, Im KS, Kim NH, Kim HW, Shin JI, Yhee JY, Sur JH. Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors. Vet Pathol. 2015b; 52(6): 1045–1051. https://doi.org/10.1177/0300985815579994

Lim HY, Seung BJ, Cho SH, Kim SH, Bae MK, Sur JH. Canine mammary cancer in overweight or obese female dogs is associated with intratumoral microvessel density and macrophage counts. Vet Pathol. 2022; 59(1): 39–45. https://doi.org/10.1177/03009858211040481

Lynch BM, Dunstan DW, Healy GN, Winkler E, Eakin E, Owen N. Objectively measured physical activity and sedentary time of breast cancer survivors, and associations with adiposity: findings from NHANES (2003-2006). Cancer Causes Control. 2010; 21(2): 283–288. https://doi.org/10.1007/s10552-009-9460-6

Mahboobifard F, Pourgholami MH, Jorjani M, Dargahi L, Amiri M, Sadeghi S, Tehrani FR. Estrogen as a key regulator of energy homeostasis and metabolic health. Biomed Pharmacother. 2022; 156: 113808. https://doi.org/10.1016/j.biopha.2022.113808

Mao C, Wang M, Li L, Tang JH. Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes. J Clin Lab Anal. 2022; 36(2): e24212. https://doi.org/10.1002/jcla.24212

Marchi PH, Vendramini THA, Perini MP, Zafalon RVA, Amaral AR, Ochamotto VA, Da Silveira JC, Dagli MLZ, Brunetto MA. Obesity, inflammation, and cancer in dogs: Review and perspectives. Front Vet Sci. 2022; 9: 1004122. https://doi.org/10.3389/fvets.2022.1004122

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer 2017; 17(246). https://doi.org/10.1186/s12885-017-3232-6

Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res. 2013; 15: R16. https://doi.org/10.1186/bcr3391

Moore SC, Playdon MC, Sampson JN, Hoover RN, Trabert B, Matthews CE, Ziegler RG. A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst. 2018; 110(6): 588–597. https://doi.org/10.1093/jnci/djx244

Motoki AH, Buttros DAB, Gaspar AL, Almeida-Filho BS, Carvalho-Pessoa E, Vespoli HDL, Nahas-Neto J, Nahas EAP. Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women. Clin Breast Cancer. 2022; 22(2): e253–e261. https://doi.org/10.1016/j.clbc.2021.07.009

Naaman SC, Shen S, Zeytinoglu M, Iyengar NM. Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation. J Clin Endocrinol Metab. 2022; 107(8): 2154–2166. https://doi.org/10.1210/clinem/dgac241

Nehme R, Diab-Assaf M, Decombat C, Delort L, Caldefie-Chezet F. Targeting adiponectin in breast cancer. Biomedicines 2022; 10(11): 2958.

https://doi.org/10.3390/biomedicines10112958

Nicchio BO, Barrouin-Melo SM, Machado MC, Vieira-Filho CH, Santos FL, Martins-Filho EF, Barbosa VF, Barral TD, Portela RW, Damasceno KA, Estrela-Lima A. Hyperresistinemia in Obese Female Dogs With Mammary Carcinoma in Benign-Mixed Tumors and Its Correlation With Tumor Aggressiveness and Survival. Front Vet Sci. 2020; 7: 509. https://doi.org/10.3389/fvets.2020.00509

Nguyen HL, Geukens T, Maetens M, Aparicio S, Bassez A, Borg A, Brock J, Broeks A, Caldas C, Cardoso F, De Schepper M, Delorenzi M, Drukker CA, Glas AM, Green AR, Isnaldi E, Eyfjörð J, Khout H, Knappskog S, Krishnamurthy S, Lakhani SR, Langerod A, Martens JWM, Reed MAE, Murphy L, Naulaerts S, Nik-Zainal S, Nevelsteen I, Neven P, Piccart M, Poncet C, Punie K, Purdie C, Rakha EA, Richardson A, Rutgers E, Vincent-Salomon A, Simpson PT, Schmidt MK, Sotiriou Christos, Span PN, Tan KTB, Thompson A, Tommasi S, Van Baelen KV, Van de Vijver M, Van Laere S, van't Veer L, Viale G, Viari A, Vos H, Witteveen AT, Wildiers H, Floris G, Garg AD, Smeets A, Lambrechts D, Biganzoli E, Richard F, Desmedt C. Obesity-associated changes in molecular biology of primary breast cancer. Nat Commun. 2023; 14: 4418. https://doi.org/10.1038/s41467-023-39996-z

Nguyen F, Peña L, Ibisch C, Loussouarn D, Gama A, Rieder N, Belousov A, Campone M, Abadie J. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Res Treat. 2018; 167: 635–648. https://doi.org/10.1007/s10549-017-4548-2

Oh JH, Cho JY. Comparative oncology: overcoming human cancer through companion animal studies. Exp Mol Med. 2023; 55: 725–734. https://doi.org/10.1038/s12276-023-00977-3

Park B, Kim S, Kim H, Cha C, Chung MS. Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women. Br J Cancer. 2021; 125: 1718–1725. https://doi.org/10.1038/s41416-021-01540-5

Park YM, White AJ, Nichols HB, O'Brien KM, Weinberg CR, Sandler DP. The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer. 2017; 140(12): 2657–2666. https://doi.org/10.1002/ijc.30684

Patrício M, Pereira J, Crisóstomo J, Matafome P, Gomes M, Seiça R, Caramelo F. Using Resistin, glucose, age and BMI to predict the presence of breast cancer. BMC Cancer 2018; 18(1): 29. https://doi.org/10.1186/s12885-017-3877-1

Pereira IC, Mascarenhas IF, Capetini VC, Ferreira PMP, Rogero MM, Torres-Leal FL. Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. Crit Rev Oncol Hematol. 2022; 179: 103796. https://doi.org/10.1016/j.critrevonc.2022.103796

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017; 67(5): 378–397. https://doi.org/10.3322/caac.21405

Queiroga FL, Pérez-Alenza MD, Silvan G, Peña L, Lopes C, Illera JC. Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol. 2005; 94(1-3): 181–187. https://doi.org/10.1016/j.jsbmb.2004.12.014

Ren X, Fan Y, Shi D, Liu Y. Expression and significance of IL-6 and IL-8 in canine mammary gland tumors. Sci Rep. 2023; 13: 1302. https://doi.org/10.1038/s41598-023-28389-3

Rosendahl AH, Bergqvist M, Lettiero B, Kimbung S, Borgquist S. Adipocytes and Obesity-Related Conditions Jointly Promote Breast Cancer Cell Growth and Motility: Associations With CAP1 for Prognosis. Front Endocrinol. 2018; 9: 689. https://doi.org/10.3389/fendo.2018.00689

Sahabi K, Selvarajah GT, Abdullah R, Cheah YK, Tan GC. Comparative aspects of microRNA expression in canine and human cancers. J Vet Sci. 2018; 19(2): 162–171. https://doi.org/10.4142/jvs.2018.19.2.162

Sankofi BM, Valencia-Rincón E, Sekhri M, Ponton-Almodovar AL, Bernard JJ, Wellberg EA. The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism. Front Endocrinol. 2023; 14: 1217875. https://doi.org/10.3389/fendo.2023.1217875

Seung BJ, Lim HY, Shin JI, Kim HW, Cho SH, Kim SH, Sur JH. CD204-Expressing Tumor-Associated Macrophages Are Associated With Malignant, High-Grade, and Hormone Receptor-Negative Canine Mammary Gland Tumors. Vet Pathol. 2018; 55(3): 417–424. https://doi.org/10.1177/0300985817750457

Shin JI, Lim HY, Kim HW, Seung BJ, Ju JH, Sur JH. Analysis of obesity-related factors and their association with aromatase expression in canine malignant mammary tumours. J Comp Pathol. 2016; 155(1): 15-23. https://doi.org/10.1016/j.jcpa.2016.05.005

Tamarindo GH, Novais AA, Chuffa LGA, Zuccari DAPC. Metabolic Alterations in Canine Mammary Tumors. Animals 2023; 13(17): 2757. https://doi.org/10.3390/ani13172757

Taroeno-Hariadi KW, Hardianti MS, Sinorita H, Aryandono T. Obesity, leptin, and deregulation of microRNA in lipid metabolisms: their contribution to breast cancer prognosis. Diabetol Metab Syndr. 2021; 13(1): 10. https://doi.org/10.1186/s13098-020-00621-4

Tong Y, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X, Shen K. IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. Front Oncol. 2020; 10: 550. https://doi.org/10.3389/fonc.2020.00550

Wu C, Dong S, Huang R, Chen X. Cancer-Associated Adipocytes and Breast Cancer: Intertwining in the Tumor Microenvironment and Challenges for Cancer Therapy. Cancers 2023; 15(3): 726. https://doi.org/10.3390/cancers15030726

Zhong W, Wang X, Wang Y, Sun G, Zhang J, Li Z. Obesity and endocrine-related cancer: The important role of IGF-1. Front Endocrinol. 2023; 14: 1093257. https://doi.org/10.3389/fendo.2023.1093257

Zhu Y, Wang T, Tong Y, Chen X, Shen K. 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients. Front Endocrinol. 2021; 12: 725161. https://doi.org/10.3389/fendo.2021.725161